Literature DB >> 34272205

The evolution of rapid antigen detection systems and their application for COVID-19 and other serious respiratory infectious diseases.

Charles S Pavia1, Maria M Plummer2.   

Abstract

Making the correct diagnosis of a patient seeking medical attention is the ultimate goal of a practicing physician, irrespective of whether the cause of the patient's condition is infectious or non-infectious. Antigen detection tests can be used to aid in the diagnosis of various infectious-related disorders including COVID-19 where it has become especially important due to the serious nature of this disease and its worldwide prevalence. These tests closely mimic one of the earliest prototypes - the urine pregnancy test - and as a result they have gained wide acceptance based on their overall simplicity, low cost and relative accuracy. In some situations, especially as a screening test, they can be used instead of the more technically demanding and complex molecular and serologic assays that are still useful and helpful under many different circumstances. Antigen detection systems are based on finding a particular immunogenic component, typically a protein or polysaccharide molecule, that is both unique and an integral part of the pathogen or other biological entity. Because these tests generally provide only qualitative results, they often need to be supplemented with other and sometimes more sophisticated laboratory-based diagnostic procedures to corroborate the initial test result. In this review, we first describe general background information on antigen-detection methods, including any unique aspects of their overall design, and then follow with an extensive description on the merits and limitations of these tests for detecting COVID-19 and, to a lesser extent, for other serious respiratory diseases caused by three common bacterial pathogens - Streptococcus pyogenes, Streptococcus pneumoniae and Legionella pneumophila.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Antigen-detection; COVID-19; Legionella pneumophila; SARS-Cov-2; Streptococcus pneumoniae; Streptococcus pyogenes

Year:  2021        PMID: 34272205     DOI: 10.1016/j.jmii.2021.06.003

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  2 in total

1.  Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay.

Authors:  Neta S Zuckerman; Itay Bar-Or; Oran Erster; Ella Mendelson; Areej Kabat; Virginia Levy; Batya Mannasse; Hadar Assraf; Roberto Azar; Yaniv Ali; Efrat Bucris; Dana Bar-Ilan; Orna Mor; Michal Elul; Michal Mandelboim; Danit Sofer; Shay Fleishon
Journal:  Microbiol Spectr       Date:  2022-03-14

Review 2.  COVID-19 Vaccines for HIV-Infected Patients.

Authors:  Maria M Plummer; Charles S Pavia
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.